Want To Nourish Your Skin And Beauty. Here Are The Products From Amazon To Help You

They discover a new effective therapeutic combination in patients with melanoma – Correo Farmacéutico – Todo Dermo

In Natural Beauty Tips

New research from the University of California (UC) found that interleukin (IL) – 2 combined with imiquimod and topical retinoid therapy in patients with so -called “transit metastasis” is a promising therapeutics option. The findings have been published in Journal of the American Academy of Dermatology .

“Our results showed that the intralesional therapy with a protein that causes immune cells to divide, administered in combination with an immune activator topically applied, can be a highly effective treatment for these patients”, said Maverakis, associate professor dermatology.

Although intralesional IL-2 has recently been included in the guidelines of the US National Cancer Network Comprenhensive for the treatment of metastatic melanoma, according to the researchers, American doctors have not been adopted yet.

About ten percent of patients with advanced melanoma development, called cutaneous metastases, often were located “in transit” in the lymph nodes of patients. Historically, treatment for these metastatic lesions were surgically removed with or without radiation therapy, but recurrences can be very high.

For the study, researchers a retrospective analysis of patients with stage III or stage IV who had the combination therapy treatment with IL-2 with imiquimod and a topical retinoid melanoma. Patients were controlled by the dermatology department between 2006 and 2015, most were elderly and had other illnesses. Ten of the 11 patients experienced disease recurrence after surgery, and several also nonsurgical treatment has failed.

The data indicated that all patients achieved complete clinical response to treated lesions one to three months of initiation of therapy based on IL-2 intralesional. After two years, 82 percent of patients were alive, and at the end of the study, seven were alive without recurrent melanoma. The remaining five patients died of unrelated causes.

More studies are needed
“The favorable results in these patients are encouraging and suggest that the therapeutic regimen may have a survival benefit , ” concluded Maverikis and the team of researchers.

The authors point out that the study has limitations which records only 11 patients were analyzed, and no experiments leading to determine the effects of the therapeutic regimen in immune systemic response.

Join Our Newsletter!

Love Daynight? We love to tell you about our new stuff. Subscribe to newsletter!

You may also read!

Top 10 Fitness Tips

It can be a daunting job to get in shape. You continue, stop, frustrate yourself. You must drop your


How To Stay Healthy In Summer

Bright sunny days, the summer breeze and having your favorite ice-cream; summer brings with itself many fun activities all


Two Tips for Aging and Self-Care

As a woman continues to progress in age, it doesn’t take long before she realizes that she’s going to


Leave a reply:

Your email address will not be published.

Mobile Sliding Menu

Translate »